Switch to fixed-dose ainuovirine, lamivudine, and tenofovir DF versus elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in virologically suppressed people living with HIV-1: the 48-week results of the SPRINT trial, a multi-centre, randomised, double-blind, active-controlled, phase 3, non-inferiority trialResearch in context

• Hlavní autoři: Fujie Zhang (Autor), Hao Wu (Autor), Weiping Cai (Autor), Ping Ma (Autor), Qingxia Zhao (Autor), Hongxia Wei (Autor), Hongzhou Lu (Autor), Hui Wang (Autor), Shenghua He (Autor), Zhu Chen (Autor), Yaokai Chen (Autor), Min Wang (Autor), Wan Wan (Autor), Heliang Fu (Autor), Hong Qin (Autor)
• Médium: Kniha
• Vydáno: Elsevier, 2024-08-01T00:00:00Z.
• Témata: article
• On-line přístup: Connect to this object online.

Summary: Background: We compared the efficacy and safety profiles of ainuovirine (ANV), a new-generation non-nucleoside reverse transcriptase inhibitor (NNRTI), with boosted elvitegravir (EVG), both coformulated with two nucleoside reverse transcriptase inhibitors (NRTIs), in people living with HIV-...